Allogene Therapeutics, Inc.: how funds voted at the meeting of 18 Jun 2026
- Ticker
- ALLO
- Meeting
- Season
- year to 30 June 2026
- Filers reporting
- 250
- Ballot items
- 5
250 filers on Form N-PX reported votes at the Allogene Therapeutics, Inc. meeting of 18 Jun 2026. The records fall into 5 ballot items. The page lists them in ballot order: items of the company first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting.
If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.
The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .
The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.
The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.
The page gives records. It gives no investment advice and no advice on how to vote.
Season on this page: year to 30 June 2026. Filings read through . How the figures are made
The ballot
Item 1: Director elections
3 nominees. 56.3% of the reported votes are for. 45 filers withheld from or voted against at least one nominee.
465 vote records from 83 filers. 29 of the 83 filers that marked the item voted against management.
- Positions of 34 fund families
- For 21
- Abstain or withhold 13
- Against management 13
Item 2: Advisory vote on executive pay (say-on-pay)
359 vote records from 248 filers. 31 of the 234 filers that marked the item voted against management. 14 filers gave no management mark.
- Positions of 38 fund families
- For 31
- Against 6
- Split or no vote 1
- Against management 5
Item 3: Frequency of the say-on-pay vote
One year: 216 filers. Three years: 7 filers. For: 5 filers. Abstain: 3 filers. Not applicable: 2 filers. 1-year: 2 filers.
362 vote records from 247 filers. 9 of the 230 filers that marked the item voted against management. 17 filers gave no management mark.
- Positions of 38 fund families
- For 1
- Split or no vote 37
- Against management 2
Item 4: Audit-related items (auditor ratification)
155 vote records from 83 filers. 1 of the 83 filers that marked the item voted against management.
- Positions of 34 fund families
- For 34
Item 5: CAPITAL STRUCTURE: management items
The company's items in this category are shown together, because filers word and number them differently.
155 vote records from 83 filers. 1 of the 83 filers that marked the item voted against management.
- Positions of 34 fund families
- For 34
Positions of the fund families
A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.
KeyForAgainstAbstain or withholdSplit or no voteAgainst management
| Fund family | 2. Say-on-pay | 3. Pay-vote frequency | 4. Auditor |
|---|---|---|---|
| AllianceBernstein | For | Split | No report |
| Allspring | Split | Split | No report |
| American Century | Against, against management | Split | For |
| BlackRock and iShares | For | Split | For |
| BNY Mellon | For | Split | No report |
| Brighthouse Funds | Against | For | For |
| Charles Schwab | For | Split | For |
| Columbia Threadneedle | For | Split | For |
| Dimensional | For | Split, against management | For |
| DWS | For | Split | For |
| Equitable | For | Split | For |
| Fidelity | For | Split | For |
| Global X | For | Split | For |
| Goldman Sachs | For | Split | For |
| Guggenheim and Rydex | For | Split | For |
| Invesco | Against, against management | Split | For |
| J.P. Morgan | Against, against management | Split | For |
| Jackson National funds | For | Split, against management | For |
| John Hancock and Manulife | For | Split | For |
| Lincoln Financial | For | Split | For |
| Macquarie and Delaware Funds | For | Split | For |
| Morgan Stanley, Eaton Vance and Calvert | Against, against management | Split | For |
| Nationwide | For | Split | For |
| Neuberger Berman | For | Split | No report |
| Northern Trust and FlexShares | For | Split | For |
| Nuveen and TIAA | For | Split | For |
| Pacific Life funds | For | Split | For |
| PGIM and Prudential | Against, against management | Split | For |
| Principal | For | Split | For |
| ProShares and ProFunds | For | Split | For |
| Russell Investments | For | Split | For |
| SEI | For | Split | For |
| State Street and SPDR | For | Split | For |
| T. Rowe Price | For | Split | For |
| Vanguard | For | Split | For |
| Victory Capital | For | Split | For |
| Voya | For | Split | For |
| WisdomTree | For | Split | For |
Questions
- How many filers reported votes at the Allogene Therapeutics, Inc. meeting?
- 250 Form N-PX filers reported votes at the meeting of 18 Jun 2026. On say-on-pay, 31 of 234 filers that marked the item voted against management (13.2%).
- Is this the result of the meeting?
- No. The page counts the filers that report on Form N-PX, and the shares they reported. Allogene Therapeutics, Inc. reports the result of a vote on Form 8-K.
- Why does the page show counts only for director elections?
- A director record names the nominee. This site has no page and no row about a person. For director elections it keeps the number of nominees and the split of votes.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Allogene Therapeutics, Inc. with a meeting date within three days of 18 Jun 2026. A proposal title is the most common wording among filers. Where a wording can name a person, the SEC category is shown. The filers wrote the filings. Filings read through .